Staging and monitoring pulmonary sarcoidosis: Pulmonary function tests and other variables

Sarcoidosis

Volumn , Issue , 2012, Pages 102-112

  Wells, Athol ^a   Parfrey, Helen ^b   Ward, Simon ^c   Cramer, Derek ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906061833     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Alhamad EH, Lynch JP, Martinez FJ (2001). Pulmonary function tests in interstitial lung disease: what role do they have? Clin Chest Med 22: 715-50.
2. ARTP (2006). Working Groups on Standards of Care and Recommendations for Lung Function Departments: Quality assurance for lung function laboratories. Available at www.ARTP.org.uk.
3. Baughman RP, Engel PJ, Meyer CA et al. (2006). Pulmonary hypertension in sarcoidosis. Sarcoid Vasc Diffuse Lung Dis 23: 108-16.
4. Baughman RP, Desai S, Drent M et al. (2009). Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 136: 526-35.
5. Braun JJ, Kessler R, Constantinesco A, Imperiale A (2008). 18 F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 35: 1537-43.
6. Brusasco V, Crapo R, Viegi G (2005a). ATS/ERS task force on standardisation of lung function testing: General considerations for lung function. Eur Respir J 26: 153-61.
7. Brusasco V, Crapo R, Viegi G (2005b). ATS/ERS task force on standardisation of lung function testing: Standardisation of the single breath determination of carbon monoxide uptake in the lung. Eur Respir J 26: 720-35.
8. BTS (2002). British Thoracic Society recommendations: Managing passengers with respiratory disease planning air travel. Thorax 57: 289-304.
9. BTS (2004). British Thoracic Society recommendations: Managing passengers with respiratory disease planning air travel -summary for primary care. Available at www.brit-thoracic.org.uk/.
10. BTS (2008). British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society: Interstitial lung disease guideline. Thorax 63(Suppl. V): 51-58.
11. Burke CM, Glanville AR, Morris AJR et al. (1987). Pulmonary function in advanced pulmonary hypertension. Thorax 42: 151-5.
12. Carrington CB (1976). Structure and function in sarcoidosis. Ann NY Acad Sci 278: 265-83.
13. Chambellan A, Turbie P, Nunes H et al. (2005). Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function and evolution. Chest 127: 472-81.
14. Costabel U, Guzman M (2001). Bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulm Med 7: 255-61.
15. Cotes JE, Chinn DJ, Miller MR (2006). Lung Function, 6th edn. Blackwell, Oxford, p. 79.
16. Cramer D, Ward S, Geddes D (1996). Assessment of oxygen supplementation during air travel. Thorax 51: 202-3.
17. Drent M, Jacobs J, de Vries J et al. (1999). Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 13: 1338-44.
18. Drent M, De Vries J, Lenters M et al. (2003). Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 13: 2462-71.
19. Ernsting J, Nicholson AN, Rainford DJ (eds). (2000). Aviation Medicine, 3rd edn. Butterworth-Heinmann, Oxford.
20. Gibson GJ, Prescott RJ, Muers MF, Mitchell DN (1996). British Thoracic Society sarcoidosis study: Effects of long-term corticosteroid treatment. Thorax 51: 238-47.
21. Gleeson FV, Traill ZC, Hansell DM (1996). Evidence of expiratory CT scans of small-airway obstruction in sarcoidosis. Am J Roentgen 166: 1052-4.
22. Grutters JC, Fellrath JM, Mulder L et al. (2003). Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 124: 186-95.
23. Hansell DM, Milne DG, Wilsher ML, Wells AU (1998). Pulmonary sarcoidosis: morphologic associations of airflow obstruction on thin section computed tomography. Radiology 209: 697-704.
24. Hansell DM, Armstrong P, Lynch DA, McAdams HP (eds). (2005). Imaging of Diseases of the Chest, 4th edn. Elsevier Mosby, St Louis, pp. 635-6.
25. Harrison BD, Shaylor JM, Stokes TC, Wilkes AR (1991). Airflow limitation in sarcoidosis: a study of pulmonary function in 107 patients with newly diagnosed disease. Resp Med 85: 59-64.
26. ILO (1980). Guidelines for the Use of ILO International Classification of Radiographs of Pneumoconioses [Occupational Safety Series 22]. International Labor Office, Geneva.
27. Joint Statement of the American Thoracic Society, European Respiratory Society and World Association of Sarcoidosis And Other Granulomatous Disorders (1999). Am J Respir Crit Care Med 160: 736-54.
28. Judson MA, Gilbert GE, Rodgers JK et al. (2008). The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology 13: 97-102.
29. Keicho N, Kitamura K, Takaku F, Yotsumoto H (1990). Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 98: 1125-9.
30. Keijsers RGM, Verzijbergen JF, van Diepen DM et al. (2008). 18 F-FDG PET in sarcoidosis: an observational study in 12 patients treated with Infliximab. Sarcoid Vasc Diff Lung Dis 25: 143-50.
31. Keogh BA, Crystal RG (1980). Pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest 78: 856-64.
32. Kohn H, Klech H, Mostbeck A, Kummer F (1982). 67-Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes. Eur J Nucl Med 7: 413-16.
33. Latsi PI, du Bois RM, Nicholson AG et al. (2003). Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168: 531-7.
34. Leung AN, Brauner MW, Caillat-Vigneron N et al. (1998). Sarcoidosis activity: correlation of HRCT findings with those of 67Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme assay. J Comput Assist Tomogr 22: 229-34.
35. Levinson RS, Metzger LF, Stanley NN et al. (1977). Airway function in sarcoidosis. Am J Med 62: 51-9.
36. Lynch JP, Kazerooni EA, Gaye SE (1997). Pulmonary sarcoidosis. Clin Chest Med 18: 755-85.
37. Martin SE, Bradley JM et al. (2007). Flight assessment in patients with respiratory disease: hypoxic challenge testing vs. predictive equations. Q J Med 100: 361-7.
38. Muller-Quernheim J, Pfeifer S, Strausz J, Ferlinz R (1991). Correlation of clinical and immunologic parameters of the inflammatory activity of pulmonary sarcoidosis. Am Rev Respir Dis 144: 1322-9.
39. Muers MF, Middleton WG, Gibson GJ et al. (1997). A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoid Vasc Diff Lung Dis 14: 46-56.
40. Nathan SD, Shlobin OA, Ahmad S et al. (2007). Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131: 657-63.
41. Neville E, Walker A, James DG (1983). Prognostic factors predicting outcome of sarcoidosis: an analysis of 818 patients. Q J Med 2: 525-33.
42. Nishiyama Y, Yamamoto Y, Fukunaga K et al. (2006). Comparative evaluation of 18F-FDG PET and 67-Ga scintigraphy in patients with sarcoidosis. J Nucl Med 47: 1571-6.
43. Oberstein A, Zitzewitz H von, Schweden F, Muller-Quernheim J (1997). Non-invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoid Vasc Diff Lung Dis 14: 65-72.
44. Remy-Jardin M, Giraud F, Remy J et al. (1994). Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology 191: 675-80.
45. Reville SM, Morgan M (2000). Biological quality control for exercise testing. Thorax 55: 63-6.
46. Roca J, Whipp BJ et al. (1997). ERS task force on standardization of clinical exercise testing: Clinical exercise testing with reference to lung diseases -indications, standardization and interpretation strategies. Eur Respir J 10: 2662-89.
47. Romer FK (1982). Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 29: 27-32.
48. Seccombe LM, Kelly PT, Wong CK et al. (2004). Effect of simulated commercial flight on oxygenation in patients with interstitial lung disease and chronic obstructive pulmonary disease. Thorax 59: 966-70.
49. Shorr AF, Torrington KG, Parker JM (1997). Serum angiotensin converting enzyme does not correlate with radiographic stage at initial diagnosis of sarcoidosis. Respir Med 91: 399-401.
50. Shorr AF, Davies DB, Nathan ST (2003). Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124: 922-8.
51. Steen VD, Graham G, Conte C et al. (1992). Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35: 765-70.
52. Stokes GS, Monaghan JC, Schrader AP et al. (1999). Influence of angiotensin converting enzyme (ACE) genotype on interpretation of diagnostic tests for serum ACE activity. Aust NZ J Med 29: 315-18.
53. Teirstein AS, Machac J, Almeida O et al. (2007). Results of 188 wholebody fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 132: 1949-53.
54. Turner-Warwick M, McAllister W, Lawrence R (1986). Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management? Thorax 41: 9903-13.
55. Ziegenhagen MW, Benner UK, Zissel G et al. (1997). Sarcoidosis: TNFalpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 156: 1586-92.
56. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J (2003). Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 21: 407-13.